Home delivery of the communicator for remote monitoring of cardiac implantable devices: A multicenter experience during the covid-19 lockdown

Michele Magnocavallo MD1 | Alessia Bernardini MD1 | Marco Valerio Mariani MD1 | Agostino Piro MD1 | Massimiliano Marini MD2 | Antonino Nicosia MD3 | Carmen Adduci MD4 | Antonio Rapacciuolo MD5 | Davide Saporito MD6 | Stefano Grossi MD7 | Giuseppe Santarpia MD8 | Paola Vaccaro MD9 | Roberto Rordorf MD10 | Francesco Pentimalli MD11 | Giuseppe Giunta MD1 | Monica Campari MS12 | Sergio Valsecchi PhD12 | Carlo Lavalle MD1

1 Department of Cardiovascular, Respiratory, Nephrology, Anaesthesiology and Geriatric Sciences, Sapienza University of Rome, Rome, Italy
2 Department of Cardiology, S. Chiara Hospital, Trento, Italy
3 Cardiology Unit, Giovanni Paolo II Hospital, Ragusa, Italy
4 Division of Cardiology, Department of Clinical and Molecular Medicine, Sapienza University of Rome, St. Andrea Hospital, Rome, Italy
5 Cardiology Unit, Università degli Studi di Napoli Federico II, Naples, Italy
6 Division of Cardiology, Infermi Hospital, Rimini, Italy
7 Cardiology Department, Azienda Ospedaliera Ordine Mauriziano, Turin, Italy
8 Division of Cardiology, Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy
9 Cardiology Unit, Riuniti Hospital, P.O. Cervello, Palermo, Italy
10 Department of Cardiology, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy
11 Cardiology Unit, San Paolo Hospital, Savona, Italy
12 Boston Scientific, Milan, Italy

Abstract
Background: During the COVID-19 pandemic in-person visits for patients with cardiac implantable electronic devices should be replaced by remote monitoring (RM), in order to prevent viral transmission. A direct home-delivery service of the RM communicator has been implemented at 49 Italian arrhythmia centers.

Methods: According to individual patient preference or the organizational decision of the center, patients were assigned to the home-delivery group or the standard in-clinic delivery group. In the former case, patients received telephone training on the activation process and use of the communicator. In June 2020, the centers were asked to

Abbreviations: CIED, Cardiac Implantable Electronic Devices; COVID-19, Coronavirus Disease 2019; CRT, Cardiac Resynchronization Therapy; ESC, European Society of Cardiology; ICD, Implantable Cardioverter Defibrillator; RM, Remote Monitoring; SARS-CoV-2, Severe Acute Respiratory Syndrome-Coronavirus-2.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2021 The Authors. Pacing and Clinical Electrophysiology published by Wiley Periodicals LLC.
reply to an ad hoc questionnaire to describe and evaluate their experience in the previous 3 months.

**Results:** RM was activated in 1324 patients: 821 (62%) received the communicator at home and the communicator was activated remotely. Activation required one additional call in 49% of cases, and the median time needed to complete the activation process was 15 min [25th-75th percentile: 10–20]. 753 (92%) patients were able to complete the correct activation of the system. At the time when the questionnaire was completed, 743 (90%) communicators were regularly transmitting data. The service was generally deemed useful (96% of respondents) in facilitating the activation of RM during the COVID-19 pandemic and possibly beyond.

**Conclusions:** Home delivery of the communicator proved to be a successful approach to system activation, and received positive feedback from clinicians. The increased use of a RM protocol will reduce risks for both providers and patients, while maintaining high-quality care.

**KEYWORDS**
cardiac implantable electronic device, covid-19, follow-up, remote monitoring

---

1 | **INTRODUCTION**

In December 2019, an outbreak of pneumonia caused by a novel coronavirus occurred in Wuhan, China. The virus was identified as severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), which causes Coronavirus disease 2019 (COVID-19), and triggered a worldwide health emergency. On March 8th, Italy became the second most severely affected country in the world, and specific restrictions on social contacts were imposed by the Italian government. In accordance with the European Society of Cardiology (ESC) guidelines for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic, patients with ambulatory stable heart failure had to refrain from hospital visits, and cardiology centers were strongly encouraged to conduct follow-up and provide patients with medical advice by means of telemedicine, in order to prevent viral transmission to patients and healthcare providers. These recommendations specifically applied to patients with cardiac implantable electronic devices (CIEDs). For these patients, in-person office visits could be replaced by remote contact, by using the device information obtained through remote monitoring (RM).

Since the beginning of the lockdown phase in Italy, Boston Scientific has communicated to all Italian centers implanting CIEDs its willingness to implement a direct home-delivery service of the LATITUDE communicator, in order to allow RM of all patients not yet monitored, without requiring access to the hospital. The initiative included delivery of the communicator, the informed consent process, and organization of remote training for patients and the staff of the center, if needed.

Here, we report the results of a questionnaire designed to evaluate the experience of the centers that adhered to the "LATITUDE at home" campaign.

2 | **METHODS**

Starting on March 20, the centers adhering to the initiative identified patients with an implanted Boston Scientific CIED with RM capabilities who were not yet enrolled in the LATITUDE platform. The staff of all centers not yet using LATITUDE received remote training in the use of the platform from the Boston Scientific technical support team. Patients were contacted and offered a communicator for RM of their devices. According to individual patient preference or the organizational decision of the center, patients were assigned to the home-delivery group or the in-clinic delivery group. In the former case, patients received telephone training on the activation process and use of the communicator; additional phone contacts were made before or after the delivery of the communicator, if deemed necessary or if requested by the patient. In the latter case, an in-clinic visit was scheduled, during which the communicator was delivered, and training was provided. Each center designed specific pathways for in-clinic visits, to guarantee patients' and workers' safety. Patients and caregivers were required to wear personal protective equipment, the clinics were sanitized between one visit and the next, the attending nurse or physician underwent COVID-19 testing periodically or if at-risk exposure was suspected. All patients were asked to perform a manual transmission upon receipt of the communicator, in order to complete the activation of the system.

In June, the centers were asked to reply to an ad hoc questionnaire to evaluate their experience in the period between March 20 and the end of May. The purpose of the questionnaire was to characterize the use of RM at the centers before the lockdown period, to describe the changes introduced during the lockdown and the use of the home-delivery service, to measure the effectiveness of monitoring in terms of successful activations and number of systems regularly transmitting data, to
TABLE 1 Survey questions on the remote monitoring (RM) service implemented at the centers, changes during the lockdown period and clinicians’ opinions of RM

| Remote monitoring at the centers that responded to the survey |  |
|---|---|
| Professionals involved in the management of remote monitoring | - Physicians 45%  
- Nurses and Physicians 55% |
| Automatic alerts enabled | - Device performance 77%  
- Arrhythmias/Clinical status 70% |

| Changes during the lockdown period |  |
|---|---|
| Frequency of scheduled remote interrogations | - Unchanged 58%  
- Increased 36%  
- Decreased 6% |
| Programming of alerts | - Yes 6%  
- No 94% |
| In-clinic scheduled visits | - All confirmed 29%  
- All cancelled 17%  
- Only in specific situations or for patients at higher risk 54% |
| Additional personnel needed to manage remote monitoring | - Yes 22%  
- No 78% |

| Clinician feedback on remote monitoring at the end of the lockdown period |  |
|---|---|
| Was remote monitoring effective in managing patients during the lockdown period? | - Yes 98%  
- No 2% |
| Did remote monitoring provide the same standard of care as that offered in traditional in-clinic visits? | - Yes 83%  
- No 17% |

assess the workload generated, and to collect feedback on the delivery method. The questionnaire consisted of 33 questions (see Supplementary material for details).

2.1 Statistical analysis

In the present report, continuous data are expressed as medians and interquartile ranges. Categorical data are expressed as percentages. Differences in proportions were compared by means of Chi-square analysis or Fisher’s exact test, as appropriate. A p-value < .05 was considered significant for all tests. All statistical analyses were performed by means of R: a language and environment for statistical computing (R Foundation for Statistical Computing, Vienna, Austria).

3 RESULTS

3.1 Participating centers

During the lockdown period, RM by means of the LATITUDE system was activated in 1324 patients at 49 Italian arrhythmia centers; a complete list of participating centers is reported in Appendix. The centers which participated in the survey accounted for 13% of all 372 arrhythmia centers operating in Italy in 2019. The participating centers were located in 13 Italian regions. Thirteen centers were located in regions with a high incidence of COVID-19 cases (>3.0 confirmed cases per 1000 population: Lombardy, Piedmont, Veneto, Trentino, Emilia, Liguria), 16 in regions with intermediate incidence (from 1.0 to 3.0 confirmed cases per 1000 population: Lazio, Tuscany, Puglia), and 20 in regions with a low incidence (<1.0 confirmed case per 1000 population: Campania, Calabria, Sicily, Sardinia). In 17 centers, 50 or more patients were being remotely monitored via the LATITUDE system before the lockdown period, in 24 centers the number was less than 50, and eight centers were not using the LATITUDE system for RM prior to the lockdown period. At the centers, remote data were routinely reviewed by the physician, or by a nurse and a physician in accordance with a ‘Primary Nursing’ model (Table 1). In addition to scheduled remote interrogations, RM was frequently used to detect device performance issues and arrhythmias or to monitor the patient’s clinical status, by enabling dedicated alerts (Table 1).

3.2 Activation and in-hospice management of RM

The median number of activations per center was 15 [25th-75th percentile: 9–33]. The median relative increase was 60% [25th-75th percentile: 15–100]. The relative increase of activations was 12% [25th-75th percentile: 10–55] in centers that remotely monitored 50
or more patients via the LATITUDE system before the lockdown period, and 100% [25th-75th percentile: 38–113] in centers that remotely monitored less than 50 patients (p = .004). By the end of the lockdown period, 50 or more patients were being remotely monitored via the LATITUDE system in 25 centers, and less than 50 in 24 centers. Twenty-eight (2%) patients refused the system. In addition, 376 patients underwent de-novo Boston Scientific CIED implantation or generator exchange during the lockdown period. They received the LATITUDE communicator before hospital discharge and were not included in the present analysis.

The management of RM during the COVID-19 pandemic did not change significantly. In most centers, the frequency of scheduled remote interrogations remained unchanged and no changes in alert programming were made. By contrast, in many centers, in-clinic evaluations were canceled or performed only in specific situations or for patients at higher risk. In order to coordinate the home delivery of communicators, remote training and activations, 20% of centers required additional staff. The vast majority of respondents agreed that RM was effective in managing patients during the lockdown period, and that it allowed them to provide the same care as that offered by traditional in-clinic visits (Table 1). Figure 1 reports the answers of the physicians regarding the usefulness of RM during the lockdown period. Most physicians stated that RM allowed them to replace scheduled in-clinic visits for device follow-up and to promptly manage alerts concerning device performance, arrhythmias and clinical status/heart failure. They also generally agreed that offering the RM service gave their patients a sense of reassurance.

3.3 | Home delivery of the communicator

As depicted in Figure 2, of the 1324 patients who agreed to receive the RM system, 503 (38%) went to the hospital to receive the system and the necessary instructions, while the remaining 821 (62%) received the communicator at home, and it was activated remotely. Patients were contacted by a physician in 67% of cases and by a nurse in the remaining 33%, in order to be trained in the activation process and the routine use of the communicator. After the first contact with the patient, activation required one additional call in 49% of cases and more than one in 39%; in 98% of cases, the phone contacts took place after the delivery of the communicator. To carry out the activation process, 12% of patients contacted the Boston Scientific dedicated technical support call center.

Overall, the median time needed to complete the activation process was 15 min [25th-75th percentile: 10–20]. The median number of communicators delivered at home was 11 per center [25th-75th percentile: 3–20] and home-delivered communicators accounted for 80% of all new activations of RM [25th-75th percentile: 50–100]. The proportion of home-delivered communicators was 50% [25th-75th percentile: 29–83] in centers situated in regions with a high incidence of COVID-19 cases, 72% [25th-75th percentile: 51–96] in regions with an intermediate incidence, and 89% [25th-75th percentile: 71–100] in regions with a low incidence (p = .175). The proportion of home-delivered communicators was 59% [25th-75th percentile: 29–78] in centers that remotely monitored 50 or more patients via the LATITUDE system before the lockdown period, and 91% [25th-75th percentile: 55–100] in centers that remotely monitored less than 50 patients (p = .005).

In the case of home delivery of communicators, the signature of the patient’s informed consent document was obtained by e-mail in 63% of cases and at the hospital in 16% of cases; consent was obtained by telephone in 16% of cases and by other methods in the remaining 5% of cases. Figure 3 shows the use of the home-delivery service, broken down by type of patient and device, at the centers that responded to the survey. The majority of centers preferred to assign a home-delivered communicator to specific subgroups of patients, that is, patients with more complex devices—implantable defibrillators (ICD) or

---

**FIGURE 1** Clinicians’ opinions of the usefulness of remote monitoring (RM) during the lockdown period [Color figure can be viewed at wileyonlinelibrary.com]
cardiac resynchronization therapy (CRT) - patients with difficulties in accessing the hospital or patients with visits scheduled shortly.

### 3.4 Activation rate and follow-up transmission

Of the 821 patients who received the communicator at home and who were remotely trained to use the system, 753 (92%) were able to perform a manual transmission in order to complete the correct activation of the system (Figure 2). The median rate of correct activation was 100% [25th-75th percentile: 100–100] in centers that remotely monitored 50 or more patients via the LATITUDE system before the lockdown period, and 95% [25th-75th percentile: 86–100] in centers that remotely monitored less than 50 patients ($p = .050$). At the time when the questionnaire was completed, 743 (90%) communicators were regularly transmitting data. Interrupted transmissions were due to unplugged communicator or because the patient was not compliant with prescribed use, not allowing to establish telemetry sessions. Of the 503 communicators delivered during in-clinic visits, 481 (96%, $p = .006$) were successfully activated and 480 (95%, $p = .001$) continued to transmit regularly. Table 2 reports clinicians’ feedback on the home-delivery service. The service was generally deemed useful in facilitating the activation of RM during the COVID-19 pandemic and possibly beyond.

### 4 DISCUSSION

This multicenter study examined the utility and feasibility of home delivery of communicators for RM. Its main findings are:

- Reorganization of RM enrollment during the lockdown period was easily achieved in a large population of CIED patients; services of comparable quality were provided, and no additional personnel was required in 78% of the centers.
- Although a higher activation rate was observed when the communicator was delivered during an in-clinic visit (95% vs. 92%, $p = .001$), the majority (92%) of patients who received the communicator at home were able to correctly finalize activation of the system. Moreover, thanks to the trans-telephonic technical support, 90% of communicators were regularly transmitting data at the time of questionnaire completion.
The home-delivery service was especially adopted for patients with ICD or CRT, those with difficulties in accessing the hospital (59%) and those whose scheduled office visit was canceled because of the lockdown (44%).

Clinician feedback on the home-delivery service was very satisfying: the service was deemed to be an efficient and useful means of managing patients during the lockdown period. In addition, 92% of clinicians were interested in continuing the use of this service.

The spread of the COVID-19 epidemic required a rapid response with regard to in-hospital activity. The primary modes of disease prevention recommended by the Center for Disease Control have involved...
limiting exposure and social distancing. To comply with these measures, the healthcare system has had to postpone elective procedures and non-essential follow-up visits, implement virtual interactions and adopt new work procedures in order to provide excellent care.\textsuperscript{10–14} This rapid reorganization has also affected CIED patients, for whom RM has proved able to replace in-person visits.\textsuperscript{15–20} As reported in the Heart Rhythm Society COVID-19 Task Force and ESC COVID-19 guidelines, in order to maintain a high degree of safety and limit face-to-face interactions, an extensive use of telehealth technologies has been necessary.\textsuperscript{11}

The safety and efficacy of RM was established a decade ago by the landmark TRUST trial, in which RM with automatic daily surveillance of ICD was able to detect actionable events more rapidly than conventional in-office visits.\textsuperscript{15} As also reported in several studies, not only does RM play a central role in preventing hospitalizations and improving survival and quality of life in patients with CIEDs, it is also a cost-effective alternative to in-person evaluations.\textsuperscript{16–25} Overall, in the context of the COVID-19 emergency, the improvement of RM coverage has facilitated continuous patient assistance and significantly reduced the risk of virus transmission among both more vulnerable populations and healthcare providers.\textsuperscript{26–28}

Our Italian multicenter study involved patients from different centers located in areas with different degrees of exposure to COVID-19, with 29 (59%) of 49 centers being located in regions with a moderate-high incidence of COVID-19 cases. A large number of patients were rapidly introduced to RM: the LATITUDE system was activated in 1324 patients, 821 (62%) of whom received the communicator at home, while 503 (38%) received it in hospital. Prior to the lockdown, most centers (91%) monitored fewer than 50 patients via the LATITUDE System, while by the end of the enrollment period 25 centers (50%) were monitoring at least 50 patients via this system. The increased number of patients enrolled was achieved thanks to the competence of the staff and their ability to reinforce patients’ feeling of being constantly assisted, both technically and clinically. Despite the higher number of patients remotely monitored, the centers did not make substantial changes to the use and organization of RM; consequently, no significant increase in resources was necessary. Furthermore, the median time required to complete the activation of RM was 15 min per patient; this was comparable to the time usually needed for in-office activation, as reported in the HomeGuide Registry.\textsuperscript{29} Moreover, only 22% of the centers required additional staff, indicating that RM is not only effective in preventing hospitalizations but also a cost-effective alternative to in-hospital follow-up.\textsuperscript{30–33} Finally, in this emergency setting, informed consent to home delivery of communicators was obtained from patients by means of e-mail or telephone, in order to avoid personal contacts. These strategies could be maintained in the future through adequate and safe online data storage or sharing systems, thereby facilitating the traceability and management of consent documents.

The results of our survey reveal general approval of RM and of the usefulness of the new service of home delivery; indeed, very few patients refused the system (n = 28, 2%). As expected, centers preferred to assign a home-delivered communicator to specific subgroups of patients (i.e., ICD, CRT-D, patients with difficulties in accessing the hospital or those with visits scheduled shortly, in order to protect these subpopulations at higher risk of COVID-19-related complications and mortality. The activation of RM required additional trans-telephonic support and, in 12% of cases, contact with the Boston Scientific dedicated technical support center. Nevertheless, patient acceptance was high, and 92% of patients who received the communicator at home were able to perform a manual transmission. Moreover, 743 (90%) communicators were regularly transmitting data at the time of questionnaire completion. There may be several explanations for why the rate of RM activation was lower in the home-delivery group than the rate recorded in a single-center experience or when the communicator was delivered in hospital: the heterogeneity of the various centers included, the short period of observation, and individual patients’ compliance or preference.\textsuperscript{13} The observation that the percentage of correct activations was higher in centers with previous greater RM activity, suggests that the experience of the center may play a role in patient training. These considerations show that the procedure needs to be better planned in order to be applied in all centers in a non-emergency setting. This is relevant, as patient training has an important role in the perception and acceptance of RM\textsuperscript{34} and in the continuity of monitoring, which is also known to be linked to patient outcome.\textsuperscript{35}

As emerged from the questionnaire, the home-delivery service received positive feedback from clinicians, 96% of whom considered it useful in order to manage patients during the COVID-19 pandemic, while 92% stated that they like to continue it beyond the lockdown. Only 4% of clinicians claimed that RM was not a useful means of patient management and 6% thought that home delivery was not efficient for RM activation. These negative views could probably be improved through more consolidated organization or by providing better assistance by medical and technical staff.

### 4.1 Limitations

Our findings are affected by potential limitations. The project was limited to a single RM platform, thus our results may not be applicable to other systems. Moreover, the participation in the initiative and in the present survey was voluntary, and this may have introduced biases. In addition, we cannot exclude possible differences in the implementation of the initiative among centers, with an impact on the degree of success. However, the overall success of the initiative is reassuring.

### 5 CONCLUSION

The increased use of a RM protocol will reduce risks for both providers and patients, while maintaining high-quality care. Home delivery of the communicator proved to be a successful approach to system activation, which is a major determinant of effective RM, and both clinicians and patients agreed on the usefulness of this model. Similarly, remotely training the patient to use the system seemed feasible.
ACKNOWLEDGMENTS

None.

AUTHOR CONTRIBUTIONS

Conception and design: Magnocavallo M, Bernardini A, Mariani MV, Lavalle C, Valsecchi S, Campari M; data collection: Marin M, Nicosia A, Adduci C, Rapacciuolo A, Saporito D, Grossi S, Santarpia G, Vaccaro P, Rordorf R, Pentimalli F; analysis and interpretation of data: Magnocavallo M, Valsecchi S, Mariani MV; drafting: Magnocavallo M, Bernardini A, Valsecchi S; critical review for important intellectual content: Valsecchi S, Campari M, Giunta G, Lavalle C.

CONFLICTS OF INTEREST

Monica Campari and Sergio Valsecchi are employees of Boston Scientific. The other authors report no conflicts.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request.

REFERENCES

1. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061.
2. Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270-273.
3. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China. N Engl J Med. 2019;382:727-733.
4. Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-1720.
5. Della Rocca DG, Magnocavallo M, Lavalle C, et al. Evidence of systemic endothelial injury and microthrombosis in hospitalized COVID-19 patients at different stages of the disease. J Thromb Thrombolysis. 2020;51:571-576.
6. Bedford J, Enria D, Giesecke J, et al. COVID-19: towards controlling of a pandemic. Lancet. 2020;395:1015-1018.
7. Fulchand S. Covid-19 and cardiovascular disease. BMJ. 2020;369:m1997.
8. Boriani G, Palmisano P, et al. AIAC Ricerca Network Investigators. Impact of COVID-19 pandemic on the clinical activities related to arrhythmias and electrophysiology in Italy: results of a survey promoted by AIAC (Italian Association of Arrhythmology and Cardiac Pacing). Intern Emerg Med. 2020;15:1445-1456.
9. Severino P, D’Amato A, Saglietto A, et al. Reduction in heart failure hospitalization rate during coronavirus disease 19 pandemic outbreak. ESC Heart Fail. 2020;7:4182-4188.
10. Mohanty S, Lakikreddy D, Trivedi C, et al. Creating a safe workplace by universal testing of SARS-CoV-2 infection in asymptomatic patients and healthcare workers in the electrophysiology units: a multi-center experience. J Interv Card Electrophysiol. 2020;1:1-6.
11. Lakikreddy DR, Chung MK, Gopinathanannair R, et al. Guidance for cardiac electrophysiology during the COVID-19 pandemic from the Heart Rhythm Society COVID-19 task force: electrophysiology section of the american college of cardiology; and the electrocardiography and arrhythmias committee of the council on clinical cardiology. Heart Rhythm Am Heart Assoc. 2020;17:e233-e241.
12. Varma N, Marrouche NF, Aguina L, et al. HRS/EHRA/APHRS/LAHRS/ACC/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic. J Am Coll Cardiol. 2020;76:1363-1374.
13. Piro A, Magnocavallo M, Della Rocca DG, et al. Management of cardiac implantable electronic device follow-up in COVID-19 pandemic: lessons learned during Italian lockdown. J Cardiovasc Electrophysiol. 2020;31:2814-2823.jce.14755.
14. Hollander JE, Carr BG. Virtually perfect? Telemedicine for Covid-19. N Engl J Med. 2020;382:1679-1681.
15. Varma N, Epstein AE, Irimpen A, Schweikert R, Love C. Efficacy and safety of automatic remote monitoring for implantable cardioverter-defibrillator follow-up: the Lumos-T safely reduces routine office device follow-up (TRUST) trial. Circulation. 2010;122:325-332.
16. Slotwiner D, Varma N, Akar JG, et al. HRS expert consensus statement on remote interrogation and monitoring for cardiovascular implantable electronic devices. Heart Rhythm. 2015;12:e69-e100.
17. Heidbuchel H, Hindricks G, Broadhurst P, et al. EuroEco (European Health Economic Trial on home monitoring in ICD patients): a provider perspective in five European countries on costs and net financial impact of follow-up with or without remote monitoring. Eur Heart J. 2015;36:158-169.
18. Ricci RP, Morichelli L, Quarta L, et al. Long-term patient acceptance of and satisfaction with implanted device remote monitoring. Europace. 2010;12:674-679.
19. Akar JG, Bao H, Jones P, et al. Use of remote monitoring of newly implanted cardioverter-defibrillators: insights from the patient related determinants of ICD remote monitoring (PREDICT RM) study. Circulation. 2013;128:2372-2383.
20. Zanotto G, D’Onofrio A, Della Bella P, et al. Organizational model and reactions to alerts in remote monitoring of cardiac implantable electronic devices: a survey from the Home Monitoring Expert Alliance project. Clin Cardiol. 2019;42:76-83.
21. Della Rocca DG, Albanese M, Placidi F, et al. Feasibility of automated detection of sleep apnea using implantable pacemakers and defibrillators: a comparison with simultaneous polysomnography recording. J Interv Card Electrophysiol. 2019;56:327-333.
22. Crossley GH. Further evidence that remote monitoring is cost-effective: it’s time for all to adopt. Heart Rhythm. 2017;14:58.
23. Luzzi M, De Simone A, Leonli L, et al. Remote monitoring for implantable defibrillators: a Nationwide survey in Italy. Interact J Med Res. 2013;2:e27.
24. Maines M, Catanzariti D, Angheben C, Valsecchi S, Comisso J, Vergara G. Intrathoracic impedance and ultrasound lung comets in heart failure deterioration monitoring: intrathoracic impedance and ultrasound lung comets. Pacing Clin Electrophysiol. 2011;34:968-974.
25. Forleo GB, Tesauro M, Panattoni G, et al. Impact of continuous intracardiac ST-segment monitoring on mid-term outcomes of ICD-implanted patients with coronary artery disease. Early results of a prospective comparison with conventional ICD outcomes. Heart. 2012;98:402-407.
26. De Larochellière H, Champagne J, Sarrazin J, et al. Findings of “focus only on health care needs.” J Cardiovasc Electrophysiol. 2020;31:2814-2823.jce.14755.
27. Iacopino S, Placentino F, Colella J, et al. Remote monitoring of cardiac implantable devices during COVID-19 outbreak: “keep people safe” and “focus only on health care needs.” Acta Cardiologica. 2020;18:1-4.
28. Aurichio A, Conte G, De Marchi A, et al. Challenges in activation of remote monitoring in patients with cardiac rhythm devices during the coronavirus (COVID-19) pandemic. Int J Cardiol. 2021;328:247-249.
29. Ricci RP, Morichelli L, D’Onofrio A, et al. Manpower and outpatient clinic workload for remote monitoring of patients with cardiac implantable electronic devices: data from the homeguide registry: manpower of cardiac device home monitoring. J Cardiovasc Electrophysiol. 2014;25:1216-1223.
30. Sequeira S, Jarvis CI, Benchouche A, Seymour J, Tadmouri A. Cost-effectiveness of remote monitoring of implantable cardioverter-defibrillators in France: a meta-analysis and an integrated economic model derived from randomized controlled trials. EP Europace. 2020;22:1071-1082.

31. Hummel JP, Leipold RJ, Amorosi SL, et al. Outcomes and costs of remote patient monitoring among patients with implanted cardiac defibrillators: an economic model based on the PREDICT RM database. J Cardiovasc Electrophysiol. 2019;30:1066-1077.

32. Burri H, Sticherling C, Wright D, Makino K, Smala A, Tilden D. Cost-consequence analysis of daily continuous remote monitoring of implantable cardiac defibrillator and resynchronization devices in the UK. Europace. 2013;15:1601-1608.

33. Della Rocca DG, Santini L, Forleo GB, et al. Novel perspectives on arrhythmia-induced cardiomyopathy: pathophysiology, clinical manifestations and an update on invasive management strategies. Cardiol Rev. 2015;23:135-141.

34. Laurent G, Amara W, Mansourati J, et al. Role of patient education in the perception and acceptance of home monitoring after recent implantation of cardioverter defibrillators: the EDUCAT study. Arch Cardiovas Dis. 2014;107:508-518.

35. Akar JG, Bao H, Jones PW, et al. Use of remote monitoring is associated with lower risk of adverse outcomes among patients with implanted cardiac defibrillators. Circ Arrhythm Electrophysiol. 2015;8:1173-1180.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Magnocavallo M, Bernardini A, Mariani MV, et al. Home delivery of the communicator for remote monitoring of cardiac implantable devices: A multicenter experience during the COVID-19 lockdown. Pacing Clin Electrophysiol. 2021;44:995–1003. https://doi.org/10.1111/pace.14251